PUK9 SEVEN YEAR TRENDS OF PHARMACY BENEFIT ERYTHROPOIESIS-STIMULATING AGENT UTILIZATION AND COST CONSIDERATIONS OF CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS
Abstract
Authors
F Vekeman RA Bailey F Lalibert M Senbetta RS McKenzie P Lefebvre